The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:10/21/2018
Start Date:February 2014
End Date:December 2019
Contact:Carol McAlear, MA
Email:cmcalear@upenn.edu

Use our guide to learn which trials are right for you!

The Assessment of Prednisone In Remission Trial (TAPIR) - Centers of Excellence Approach

This study is a multi-center randomized controlled trial to evaluate the effects of using
low-dose prednisone as compared to stopping prednisone treatment entirely. Participants will
be randomized 1:1 to taper their prednisone dose down to 5 mg/day or to 0 mg/day for the
duration of the study (approximately six months) or until a study endpoint.

Patients with granulomatosis with polyangiitis (GPA, Wegener's) will be recruited at one of
the Vasculitis Centers of Excellence. Participants will be randomized 1:1 either to taper
their prednisone dose down to 5 mg/day according to a standardized schedule and stay at 5
mg/day of prednisone for the duration of the study or until a study endpoint, or taper their
prednisone dose down to 0 mg/day using a standard schedule and stay at 0 mg/day for the
duration of the study or until a study endpoint. All study participants will be followed for
6 months (from reaching a prednisone dose of 5 mg/day) or until an increase of prednisone
dose (after randomization) occurs, whichever comes first.

Participants will have up to four study visits, a screening visit (visit 1), a baseline
(visit 2), a month 3 visit (visit 3) and a month 6 or flare visit (visit 3) and up to two
follow-up phone calls from the study coordinator at randomization and at month 1
(randomization and 1 month phone call may be combined if randomization occurs at month 1).

This study is a project of the Vasculitis Clinical Research Consortium (VCRC) funded through
the National Institutes of Health Rare Diseases Clinical Research Network (RDCRN) with the
purpose of promoting vasculitis research. The VCRC is the major clinical research
infrastructure in North America for the study of vasculitis, and eight VCRC Centers of
Excellence will be recruiting for this study.

Inclusion Criteria:

1. Established diagnosis of granulomatosis with polyangiitis (GPA) where patients will
need to meet at least 2 of the 5 for the classification of GPA, at least one of which
must be criterion d or e:

The modified American College of Rheumatology (ACR) criteria are:

A. Nasal or oral inflammation, defined as the development of painful or painless oral
ulcers or purulent or bloody nasal discharge.

B. Abnormal chest radiograph, defined as the presence of nodules, fixed infiltrates,
or cavities.

C. Active urinary sediment, defined as microscopic hematuria (>5 red blood cells per
high power field) or red blood cell casts.

D. Granulomatosis inflammation on biopsy, defined as histologic changes showing
granulomatous inflammation within the wall of an artery or in the perivascular or
extravascular area. Note: Pauci-immune glomerulonephritis seen on kidney biopsy will
suffice for this criterion.

E. Positive anti-neutrophil cytoplasmic antibody (ANCA) test specific for proteinase-3
measures by enzyme-linked immunoassay.

Patients who are myeloperoxidase (MPO) positive or ANCA negative are still eligible
for this study if they meet the criteria above and are felt to have GPA.

2. Active disease within the prior 12 months (initial presentation or relapse) that at
time of active disease required treatment with prednisone >20 mg/day.

3. Disease remission at time of enrollment.

4. Prednisone dose at time of enrollment of ≥ 5 mg/day and ≤ 20 mg/day.

5. Participant age of 18 years or greater.

6. If the patient is taking an immunosuppressive medication agent other than prednisone
(maintenance agent) then the maintenance agent must be at a stable dose for one month
prior to enrollment with no plans by the treating physician to change the dose (other
than for safety purposes/toxicity) for the duration of the study (through the month 6
visit or early termination). Acceptable maintenance agents include azathioprine,
leflunomide, 6-mercaptopurine, methotrexate, mycophenolate mofetil, mycophenolate
sodium, or rituximab. Patients may be on trimethoprim/sulfamethoxazole (TMP/SMX) for
use as either a maintenance agent or for prophylaxis for infection. TMP/SMX may be
used in combination with other drugs.

6.1 If the patient is regularly taking trimethoprim/sulfamethoxazole at any dose then the
patient is eligible if there no plans by the treating physician to change the dose after
enrollment (other than dose reduction or discontinuation for safety purposes/toxicity) for
the duration of the study.

Exclusion Criteria:

1. Comorbid condition that has moderate likelihood of requiring a course of prednisone
within one year of enrollment (e.g. chronic obstructive pulmonary disease (COPD), asthma,
adrenal insufficiency).
We found this trial at
7
sites
201 Presidents Circle
Salt Lake City, Utah 84108
801) 581-7200
Principal Investigator: Curry Koening, MD, MS
University of Utah Research is a major component in the life of the U benefiting...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: Carol A Langford, MD, MHS
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
4200 Fifth Ave
Pittsburgh, Pennsylvania 15260
(412) 624-4141
Principal Investigator: Larry Moreland, MD
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
One Silber Way
Boston, Massachusetts 02215
(617) 353-2000
Boston University Boston University is no small operation . With over 33,000 undergraduate and graduate...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Hamilton, Ontario
Principal Investigator: Nader Khalidi, MD
?
mi
from
Hamilton,
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Principal Investigator: Peter A Merkel, MD, MPH
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Ulrich Specks, MD
?
mi
from
Rochester, MN
Click here to add this to my saved trials